The Spectranetics Corporation was founded in the 1980s on excimer laser technology and today markets the only Excimer Laser System approved in the United States, Canada, Europe and Japan for use in minimally invasive interventional procedures within the cardiovascular system. High-energy, ultraviolet light vaporizes blockages into small particles that are absorbed into the bloodstream, reducing complications and improving clinical outcomes.
The Company’s Vascular Intervention business line manufactures and sells a range of peripheral and cardiac laser catheters for ablation of stenosed and occluded arteries above and below the knee and within coronary arteries. The Company also produces aspiration and support catheters.
The Lead Management business line includes the manufacturing of excimer laser sheaths and cardiac lead management accessories, including lead locking stylets for manual traction and aid in laser-assisted extraction of cardiac pacemaker and defibrillator leads.
Spectranetics was founded in 1984 by Robert Golobic, Ph.D., a United States Air Force physicist, and Johan Sverdrup, a Hewlett-Packard engineer. Golobic was working on lasers as part of the Strategic Defense Initiative and Sverdrup had done ultrasound work with Advanced Diagnostic Research (ADR) and Doppler imaging with Vingmed. Together they created Spectranetics — one of the first companies in the world to explore the possibility of using an ultraviolet laser to clear occluded arteries. The first patient was treated at the Texas Heart Institute in 1989.
In 1993, Spectranetics received Food and Drug Administration (FDA) clearance for its laser ablation system and fiber optic catheters for use in the treatment of coronary artery disease. Four years later the company received clearance for use of the laser sheath in the removal of pacemaker and implantable cardioverter defibrillator (ICD) leads.
In the year 2000, trials began in the treatment of peripheral artery disease. The FDA granted clearance in 2004 to treat patients suffering from total occlusions refractory to a guidewire in leg arteries. In 2007, the Company’s Turbo-Booster® received FDA clearance to treat arterial blockages above-the-knee. In 2008 the Company acquired three endovascular products from Kensey Nash Corporation, expanding the product portfolio to include aspiration catheters and a thombectomy system for removal of thrombus. In 2009, the Company received initial clearance for Turbo-Tandem; following several engineering enhancements, we received additional clearance in January 2010, with a full market launch in March 2010.
Today over 800 laser systems are in use around the world. Thousands of physicians safely use Spectranetics products, touching countless patients who’ve made positive changes in their lives thanks to technology available in the fight against cardiovascular diseases.